Literature DB >> 14679791

[Endothelium-dependent vasodilation in type II diabetes mellitus].

Machi Furuta1, Keiko Tsunoda, Mikio Arita, Kishio Nanjo, Tokio Sanke.   

Abstract

Endothelial dysfunction is a major feature of atherosclerosis and it can also serve as an early atherosclerotic marker. Evaluation and assessment of the endothelial function is important to prevent serious atherosclerotic disease especially myocardial infarction, cerebrovascular disease and renal failure. To evaluate endothelial function we measured endothelium-dependent vasodilation (flow-mediated dilatation: %FMD) of the brachial artery with ultrasound. This method is non-invasive and can be repeatable in order to follow patients individually. Progressive atherosclerosis is often observed in diabetic patients who are not hypertensive. To evaluate the impairment of the endothelial function in type 2 diabetic patients, we examined %FMD in them and compared with hypertensive patients without diabetes and control subjects. We found that type 2 diabetic patients had the same endothelial dysfunction as hypertensive patients without diabetes. %FMD in both diabetic patients and hypertensive patients was lower than in control subjects. Moreover, %FMD of type 2 diabetic patients with hypertension was lower than %FMD of type 2 diabetic patients without hypertension. These finding suggests that endothelial dysfunction develops under the conditions of hypertension and hyperglycemia. Evaluating endothelial function with ultrasound is useful for assessment of atherosclerosis in diabetes.

Entities:  

Mesh:

Year:  2003        PMID: 14679791

Source DB:  PubMed          Journal:  Rinsho Byori        ISSN: 0047-1860


  1 in total

1.  Combined examination of glyceryl trinitrate-mediated vascular dilation with flow-mediated vascular dilation is essential for assessment of vascular function in type 2 diabetes.

Authors:  Machi Furuta; Minoru Ueyama; Shuhei Morita; Akiko Yamana; Tokio Sanke
Journal:  J Diabetes Investig       Date:  2012-12-11       Impact factor: 4.232

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.